SEARCH RESULTS FOR: "Tag: XLV"
REFINE YOUR SEARCH:
ARTICLES/BLOGS
2017(13)
2016(1)
2015(1)
CATEGORIES
5-Minute Market Rundown(2)
Bernie's Content(2)
Best and Worst Stocks(1)
By the Numbers(2)
General(1)
Indexes and ETFs(8)
Intraday Option Activity(5)
Quantitative Analysis(2)
Stock Market News(2)
Stocks On the Move(2)
Technical Analysis(1)

10/27/2017 2:43 PM
It's been a rough week for biotech stocks, due to a handful of earnings disappointments and concerns about Amazon's (AMZN) entry into the pharmaceutical sector. As such, the SPDR S&P Biotech ETF (XB...
10/24/2017 3:51 PM
It's been a strong year for the biotech sector, with the SPDR S&P Biotech ETF (XBI) and Health Care Select Sector SPDR Fund (XLV) boasting year-to-date gains of 42% and 20%, respectively. Against this...
10/17/2017 3:34 PM
Healthcare stocks are in focus today, after Senators Lamar Alexander and Patty Murray -- a Tennessee Republican and Washington Democrat, respectively -- announced a bill to reinstate federal subsidie...
9/12/2017 3:55 PM
September is historically been a weak month for the Health Care Select Sector SPDR Fund (XLV). According to data from Schaeffer's Quantitative Analyst Chris Prybal, the fund has averaged a 1.7% loss i...
6/27/2017 1:37 PM
Biotech stocks have been hot lately, with the SPDR S&P Biotech ETF (XBI) flirting with annual highs. What's more, the exchange-traded fund (ETF) is one of the best to own in the month of July, histor...

Welcome to Schaeffer's Investment Research! We are a privately held provider of stock and options trading recommendations, options education, and market commentary, headquartered in Cincinnati, Ohio. Founded in 1981 by industry pioneer Bernie Schaeffer, we've since become a trusted source of research and analysis for individual investors and major financial media outlets alike.







Partner Center